

Iclusig (ponatinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WE	IGHT (LB/KG): ALLERGIES:			

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI DISCLOSURE AUTHORIZATION.PDF</u>

PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:		

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAP	(INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page







Iclusig (ponatinib) **Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1 HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
 Chronic Myeloid Leukemia(CML) Acute Lymphoblastic Leukemia(ALL) Other diagnosis: 				
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	I: PLEASE PROVIDE ALL RELEVANT CLIN	ICAL INFORMATION TO SUPPORT A		
trial? 🗆 Yes 🗆 No	atient as part of a treatment regimen s			
	eevec(imatinib)?	-		
Has patient had a previous trial of Sp	rycel(dasatinib)?	rovide dates of treatment.		
Has patient had a previous trial of Ta	signa(nilotinib)? Yes No <i>Please pr</i>	ovide dates of treatment.		
Has patient had a previous trial of Bo	sulif(bosutinib)? 🗆 Yes 🛛 No <i>Please pr</i>	rovide dates of treatment.		
Does patient have Philadelphia chron documentation.	nosome positive ALL(Ph+ALL)? 🗆 Yes	□ No Please submit chart		
	-positive CML (chronic phase, accelerat submit a tumor genetics analysis repor			
For Newly diagnosed answer the following: Does the patient have a diagnosis of newly diagnosed Philadelphia chromosome positive or BCR-ABL1-postive ALL? Yes Do Please submit chart documentation.				
Does patient have an ECOG performance status of less than or equal to 2? Yes No 				
Does patient have a history or current diagnosis of chronic phase, accelerated phase, or blast phase chronic myeloid leukemia(CML)? Yes No				
	rith any systemic anticancer therapy(inc for ALL?	•		
Has patient been treated with no mo chart documentation.	re than one cycle of chemotherapy ind	luction? • Yes • No Please submit		
© 2017–2023 by Magellan Rx Management, LLC Revision Date: 4/15/24 CAT0295 Page 2 of 3	. All Rights Reserved.			





Iclusig (ponatinib) **Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: ____

Will patient use Iclusig(ponatinib) in combination with chemotherapy?
Yes No Please submit chart documentation.

Will patient continue to use Iclusig(ponatinib) in combination with chemotherapy for up to 20 months? 🗆 Yes 👘 No Please submit chart documentation.

Will patient use Iclusig(ponatinib) as initial monotherapy for their newly diagnosed Philadelphia chromosome positive or BCR-ABL1-postive ALL?
Ves
No

Renewal Request:

Does patient continue to demonstrate a positive clinical response?
Ves Does patient continue to demonstrate a positive clinical response? documentation.

For patient's who have been treated for newly diagnosed Philadelphia chromosome positive or BCR-ABL1-postive ALL, is patient continuing to use Iclusig(ponatinib) in combination with chemotherapy?
Q Yes Q No Please submit chart documentation.

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: Date: Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in re liance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

> FAX THIS FORM TO: 800-424-7640 MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program Attn: CP - 4201 P.O. Box 64811 St. Paul. MN 55164-0811

